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The tumor suppressor protein p16INK4a (p16) is a well-established hallmark 
of aging that induces cellular senescence in response to stress. Previous studies 
have focused primarily on p16 regulation at the transcriptional level; comparatively 
little is known about the protein’s intracellular localization and degradation. The 
autophagy-lysosomal pathway has been implicated in the subcellular trafficking 
and turnover of various stress-response proteins and has also been shown to 
attenuate age-related pathologies, but it is unclear whether p16 is involved in this 
pathway. Here, we investigate the role of autophagy, vesicular trafficking, and 
lysosomal degradation on p16 expression and localization in human epithelial 
cells. Time-lapse fluorescence microscopy using an endogenous p16-mCherry 
reporter revealed that serum starvation, etoposide, and hydrogen peroxide 
stimulates autophagy and drives p16 recruitment to acidic cytoplasmic vesicles 
within 4 hours. Blocking lysosomal proteases with leupeptin and ammonium 
chloride resulted in the accumulation of p16 within lysosomes and increased total 
p16 levels suggesting that p16 is degraded by this pathway. Furthermore, 
autophagy blockers chloroquine and bafilomycin A1 caused p16 aggregation 
within stalled vesicles containing autophagosome marker LC3. Increase of p16 
within these vesicles coincided with the accumulation of LC3-II. Knockdown of 
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autophagosome chaperone p62 attenuated the formation of p16 aggregates in 
lysosomes, suggesting that p16 is targeted to these vesicles by p62. Taken 
together, these results implicate the autophagy pathway as a novel regulator of 
p16 degradation and localization, which could play a role in the etiology of cancer 
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CHAPTER 1: INTRODUCTION 
 
p16INK4a is important for both aging and cancer 
The tumor suppressor protein p16INK4a (CDKN2A, p16) is a member of the 
INK4 family of cyclin-dependent kinase inhibitors, which play a critical role in cell 
cycle regulation. Expression of p16 prevents cellular proliferation by binding and 
inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6). In response to oncogene 
expression and prolonged DNA damage, p16 induces a state of permanent cell 
cycle arrest known as  cellular senescence (Serrano, 1997). As an organism ages, 
p16 accumulates in tissues, which also correlates with an increase in senescent 
cells. This correlation is so strong that p16 is commonly used as a biomarker for 
cellular senescence and aging (Krishnamurthy et al., 2004). Senescence is linked 
to a myriad of diseases, especially aging-associated diseases like age-related 
macular degeneration and osteoarthritis (Childs, Durik, Baker, & van Deursen, 
2015; Jeon, David, Campisi, & Elisseeff, 2018; Kozlowski, 2012). Furthermore, the 
occurrence of p16-positive cells in vivo has been shown to shorten lifespan in mice 
(Baker et al., 2016). The link between senescence and disease has led 
researchers to begin designing therapies targeted toward eliminating senescent 
cells. In fact, clearance of p16 expressing senescent cells has been found to delay 
the onset of aging diseases, increase lifespan, and decrease rates of 
tumorigenesis in mice (Baker et al., 2016; Baker et al., 2011). For these reasons, 
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p16 should be of great interest to investigators developing anti-aging and 
rejuvenation therapies. 
In addition to aging, p16 (or more accurately, the silencing of p16 expression) 
has been suggested as a cancer biomarker, given that its negative expression is 
correlated with both tumorigenesis and tumor progression (Rocco & Sidransky, 
2001; Ruas & Peters, 1998; Sherr & McCormick, 2002). Mutations in p16 are 
associated with increased risk for a wide variety of cancers including esophageal, 
gastric, pancreatic, and skin cancer. In fact, loss of p16 has been recognized as 
one of the most common defects in all of human cancer, second only to p53 (Serra 
& Chetty, 2018). Despite this, repression of p16 has also been reported in cancer 
cell lines that contain a genetically normal p16 locus (Gonzalez-Zulueta et al., 
1995). For this reason, studying p16 regulation at both the genetic and epigenetic 
levels is of great interest to researchers in the cancer field. 
Epigenetic studies of p16 regulation are important and incomplete 
Misregulation of the p16 locus is commonly observed in human cancers and a 
wide variety of diseases. Although many disease-associated mutations within the 
p16 locus have been identified, the epigenetic factors that control p16 expression 
have not been fully described. Transcription of p16 is known to be under strict 
epigenetic control by factors such as CpG methylation and histone methylation by 
the polycomb repressor complex, however, research outside of these factors 
remains limited. For this reason, high-content epigenetic drug screens for 
modulators of p16 expression are an important tool for discovering potential 
therapeutic targets for treating aging-associated diseases and cancer. 
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p16 degradation and intracellular localization is not well described 
Along with the epigenetic regulation of p16, studies about the localization and 
degradation of the p16 protein are lacking. p16 has been reportedly expressed in 
both the nucleus and the cytoplasm (Lu et al., 2014; Nilsson & Landberg, 2006);. 
Whereas the role of p16 in the nucleus as an inhibitor of CDK4/6 is well 
understood, its subcellular localization and function in the cytoplasm remains 
mysterious. Immunohistological studies of patient tumors have suggested p16 
localization as a possible indicator of clinical prognosis. However, many of these 
studies present contradictory claims that indicate a complex role for p16 
localization in tumor progression. For example, cytoplasmic p16 has been reported 
to be a predictor of poor prognosis in patients with astrocytic brain tumors (Arifin 
et al., 2006). However, cytoplasmic p16 has also been reported as correlating with 
the absence of metastasis in other cancer types, such as melanoma (Mihic-Probst 
et al., 2006). Commonly used chemotherapeutic drugs, such as etoposide, can 
induce senescence (Petrova, Velichko, Razin, & Kantidze, 2016), but whether and 
to what extent these agents affect p16 localization has not been fully explored. 
Interestingly, p16 does not have a known nuclear localization signal (NLS) or a 
nuclear export signal (NES) (Dok, Abbasi Asbagh, Van Limbergen, Sablina, & 
Nuyts, 2016), suggesting that an indirect mechanism of intracellular transport is 
responsible for shuttling p16 between different cellular compartments (Y. B. Hu, 
Dammer, Ren, & Wang, 2015). 
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Autophagy and p16 are linked by a shared association with cellular 
senescence and aging 
 
One potential mechanism for regulation of p16 localization is vesicular 
trafficking via the lysosomal endomembrane system. Lysosomes are cytoplasmic 
organelles involved in autophagy-mediated protein degradation. Like p16, 
lysosomes are involved in senescence-associated signaling pathways, and 
lysosome dysfunction has been linked to a myriad of age-related pathologies and 
a decrease in lifespan (Carmona-Gutierrez, Hughes, Madeo, & Ruckenstuhl, 2016; 
Lee et al., 2006; Platt, Boland, & van der Spoel, 2012). Similarly, lysosomes have 
also been targeted for lifespan extension therapies, such as intervention with 
rapamycin (Carmona-Gutierrez et al., 2016). Recent studies have expanded 
beyond protein degradation and explored the role of lysosomes in subcellular 
localization of stress-response proteins and the regulation of cell fate. For 
example, the mechanistic target of rapamycin (mTOR) was found to not only be 
recruited and degraded by lysosomes, but also play an important role in lysosome 
formation and regulation of the entire autophagy pathway (Y. Hu et al., 2016).  
Given the correlation of both autophagy and p16 expression with cellular aging 
and senescence, an intriguing hypothesis is that p16 localization, degradation, and 
regulation may be mediated by lysosomes and other members of this pathway. 
Previous experiments have shown that p16 can be degraded by the proteasome 
(Ben-Saadon et al., 2004); however, no literature exists to support whether 
regulation can also occur through other known degradation mechanisms such as 
the autophagy/lysosomal pathway. Therefore, it stands to reason that studies 
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exploring the links between autophagy, senescence, and p16 remain incomplete 
and further investigation could reveal potential novel pathways governing cellular 
senescence, aging, and cancer. 
Human retinal pigment epithelial cells as a model for studying p16 
 
Retinal pigment epithelial (RPE) cells are responsible for absorbing light, 
transporting nutrients to photoreceptors, and providing the tight junctions that 
compose the blood-retinal barrier of the eye (Strauss, 2005). Senescence and 
autophagy dysfunction in RPE cells are linked to a myriad of diseases related to 
the eye, including age-related macular degeneration (Blasiak et al., 2017; 
Golestaneh, Chu, Xiao, Stoleru, & Theos, 2017). Cultured RPE cells have been 
used as human cell models for studies on cellular stress, including oxidative stress, 
as well as drug development and epigenetic research (Culver-Cochran & 
Chadwick, 2012; Fragoso et al., 2012). Accordingly, we chose an RPE cell line 
(RPE-1) as our human model for studying p16 expression and localization in 
response to autophagy, cellular stress, and drug-targeted inhibition of epigenetic 
factors. 
Summary of findings 
In these studies, we investigated the relationship between p16, cellular stress, 
and the autophagy/lysosomal pathway in human cells. We also performed an 




To investigate p16 and autophagy, we subjected human RPE-1 cells to three 
cellular stresses that have previously been shown to induce both autophagy and 
cell-cycle arrest: nutrient deprivation via serum starvation, oxidative stress via 
hydrogen peroxide, and genotoxic stress via the chemotherapeutic drug etoposide 
(Katayama, Kawaguchi, Berger, & Pieper, 2007). By engineering a live-cell 
reporter for p16, we found that activation of autophagy caused p16 to accumulate 
in acidic cytoplasmic vesicles within 24 hours. RPE-1 cells treated with lysosomal 
protease inhibitors leupeptin and NH4Cl displayed strong co-localization between 
p16 and lysosomes and increased total p16 levels. Furthermore, blocking 
autophagosome-to-lysosome fusion led to increased levels of p16 within LC3-
positive vesicles. Knockdown of autophagosome chaperone protein p62 
diminished the ability of p16 to aggregate and colocalize with lysosomes. Taken 
together, these results show that p16 is localized and degraded through the 
autophagy/lysosomal pathway, implicating the autophagy pathway as a regulator 
of p16 and senescence. 
Along with the localization and expression of p16 in response to cellular stress 
and autophagy, we also performed a high-content epigenetic screen for 
modulators of p16 expression. The screen revealed HDAC inhibitors to be potent 
repressors of p16 transcription. Targeting members of the polycomb repressor 
complex, BET family, and Menin-MLL resulted in p16 upregulation. 
These research projects contribute to the aging and cancer fields by 
showcasing novel localization, expression, regulatory, and degradation dynamics 
of the aging biomarker and tumor suppressor p16. The ability to prevent healthy 
7 
 
cells from senescing, while inducing cell-cycle arrest in transformed cells, is a 
major goal for both the aging and cancer fields. As such, these projects provide a 








CHAPTER 2: DEVELOPMENT OF A P16INK4A REPORTER CELL LINE TO 
STUDY EXPRESSION AND LOCALIZATION DYNAMICS USING 




Proteins should not be viewed as rigid structures sequestered to specific 
locations within the cell, but rather as dynamic entities that are assembled, 
translocated to different subcellular compartments, and degraded at different 
rates. Different proteins have different turnover rates, and these rates can change 
drastically in response to external perturbations. In fact, recent research has 
demonstrated that protein dynamics, rather than bulk accumulated protein levels, 
can be a better determinant of cell fate decisions, such as proliferation or 
senescence (Purvis et al., 2012; Purvis & Lahav, 2013). Accordingly, researchers 
seeking a holistic understanding of their protein of interest must employ new 
methods and technology to study protein expression and localization over time. 
Autophagy is a highly dynamic process involving rapid protein transport and 
turnover known as autophagic flux. As a consequence, many autophagy markers 
and proteins targeted for degradation are difficult to measure (Loos, du Toit, & 
Hofmeyr, 2014; Yoshii & Mizushima, 2017). Immunostaining of fixed cells can 
capture protein localization only at a single point in time. Furthermore, 
permeabilization using harsh detergents can destroy membrane-bound organelles 
such as endosomes, lysosomes, and autophagosomes (Goldenthal, Hedman, 
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Chen, August, & Willingham, 1985). As an alternative approach, fluorescently 
tagged protein reporters have been employed to accurately visualize and track 
temporal changes of members of the autophagy pathway and proteins destined to 
this pathway for degradation (Loos et al., 2014; Yoshii & Mizushima, 2017). 
Creating a live-cell fluorescent p16 reporter using CRISPR 
 
To monitor p16 protein expression and localization in real time, we developed 
a live-cell reporter in human RPE-1 cells. A fluorescent p16-mCherry fusion protein 
was incorporated at the endogenous p16 locus in RPE-1 cells using a 
CRISPR/Cas9-mediated strategy (Ran et al., 2013). A plasmid encoding a Cas9 
nuclease and guide-RNA targeting a PAM site near the p16 stop codon was co-
transfected in RPE-1 cells with a plasmid encoding a donor DNA repair template. 
The repair template consisted of a linker sequence, followed by an mCherry 
fluorescent protein with a stop codon, all of which was surrounded by “homology 
arms” designed for homology-driven repair (Figure 1). The linker sequence 
consisted of 12 glycine and serine amino acid residues, which provided a flexible 
link between p16 and the fluorescent protein. mCherry was selected because of 
its pH stability and ability to maintain fluorescence under acidic conditions, 
including within the lysosomal lumen (Bjorkoy et al., 2009; Shaner, Steinbach, & 
Tsien, 2005). The homology arms containing the homologous DNA sequences 800 
bp up- and downstream of the native p16 stop codon. Incorporation of this donor 
sequence resulted in the creation of an endogenously-tagged p16-mCherry fusion 
reporter cell line (henceforth referred to as RPE p16-mCherry), which was 
10 
 
validated to accurately measure p16 expression and localization for quantitative 
live-cell fluorescence experiments (Figure 2A-G). 
Dynamics of p16 in response to autophagy and cellular stress 
 
Using our engineered live p16-reporter cell line, we first asked how p16 
expression and localization changes in response to autophagy and cellular stress. 
To do this, we subjected RPE p16-mCherry cells to serum starvation, hydrogen 
peroxide, or etoposide treatment. To monitor the activation of autophagy, cells 
were also treated with Lysotracker, a live-cell chemical stain for V-ATPase activity 
in acidified vesicles. After 24 hours, DMSO-treated control cells exhibited sparse 
Lysotracker staining, as well as diffuse cytoplasmic p16-mCherry, demonstrating 
that p16 is expressed and autophagy is inactive under basal conditions (Figure 
3A). In contrast, serum starvation, hydrogen peroxide and etoposide induced 
bright cytoplasmic puncta in response to Lysotracker staining, demonstrating that 
these treatments were sufficient to trigger autophagy. Moreover, these cells 
accumulated cytoplasmic p16-mCherry puncta that co-localized with Lysotracker, 
demonstrating that p16-mCherry localizes to acidic cytoplasmic compartments in 
response to these stresses. Time-lapse images revealed that p16-mCherry puncta 
began forming 4 hours after treatment and increased over the course of 24 hours 
(Figures 3B and 3C). Furthermore, growth-curve analysis revealed all three 
treatments that induced p16-mCherry puncta were also sufficient to induce cell-
cycle arrest (Figure 3D). 
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Together, these data suggest that cellular stress induced by nutrient 
starvation, oxidative damage, or DNA damage, halts the cell-cycle, induces 
autophagy, and sequesters p16 to acidic compartments in the cytoplasm. 
Recruitment of p16 to these compartments occurred within 4 hours after exposure 
to these stresses and continued for at least 24 hours. These results implicate the 
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Figure 2. Development of a human RPE p16-mCherry reporter cell line. 
A) Schematic for CRISPR-mediated incorporation of a (Gly/Ser)12 linker and mCherry fluorescent 
protein at the p16/CDKN2A stop codon of RPE-1 cells. B) Immunofluorescence staining of fixed 
RPE p16-mCherry cells. Native p16-mCherry in red. p16-antibody in green. Scale bars = 100 μm.  
C) Live RPE p16-mCherry cells transfected with siRNA-p16 or scramble control for 24 hours. Scale 
bars = 100 μm. D) RT-qPCR of siRNA-transfected cells with primers for p16 or mCherry. 
Transcripts normalized to RPS9 and fold-change relative to respective scramble control are shown. 
Statistical significance determined by two-tailed t-test (n = 3). E) Western blot stained for p16 from 
RPE-1 and RPE p16-mCherry cells treated with siRNA targeting p16 (si-p16) or scramble control 
(Sc). Predicted p16 molecular weight = 16 kD. Predicted p16-mCherry molecular weight = 44 kD. 
F) Sequencing near p16 stop codon of parental RPE-1 line used to create RPE p16-mCherry line. 
Stop codon and sequence used for 3’-homology arm underlined. G) Sequencing near mCherry-
p16 stop codon of RPE p16-mCherry line. mCherry bolded. Stop codon and homology arm 




Figure 3. Dynamics of p16 localization in response to autophagy stimulation. 
RPE p16-mCherry cells were treated with DMSO, etoposide (20 μM), H2O2 (200 μM), or serum 
starved for 24 hours. A) Fluorescent p16-mCherry shown in red; Lysotracker staining of acidic 
organelles shown in green. Scale bars = 10 μm. B) Time-lapse images of p16-mCherry cells after 
treatments. C) Quantification of time-lapse images showing total mean per frame of mean p16-
mCherry puncta per cell. 1 hr = 3 frames. n > 200 cells per frame for each condition. Shading 
represents standard error of the mean. D) Relative cell growth rate for each condition quantified by 







CHAPTER 3: EFFECTS OF CELLULAR STRESS, AUTOPHAGY, AND 





Here, we asked how disruption of autophagy affects the expression and 
subcellular localization dynamics of p16. The autophagy-mediated protein 
degradation pathway involves the acidification of lysosomes in order to activate 
low-pH dependent proteases within the lysosomal lumen. Live-cell experiments 
using a p16-mCherry reporter cell line revealed co-localization between p16-
mCherry and acidic organelles, which may be lysosomes. In order to confirm this 
finding in a non-reporter cell line, we tested if blocking lysosomal degradation in 
unmodified RPE-1 cells while stimulating autophagy resulted in the accumulation 
of p16 within lysosomes.  
As shown in Figure 4, the autophagy pathway consists of several sequential 
steps, beginning with stimulation by nutrient starvation or cellular stress, followed 
by interaction between autophagosomes and lysosomes, and ending with the 
lysosomal degradation of proteins. Ubiquitinated proteins or protein aggregates 
can be targeted for lysosomal degradation by ubiquitin-binding protein p62 (also 
known as sequestosome 1; SQSTM1). p62-bound proteins are enveloped by 
autophagosomes, which are identifiable by autophagosome marker Membrane-
bound microtubule-associated protein 1A/1B-light chain 3 (LC3). Autophagosomes 
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then fuse to lysosomes (identifiable by Lysosomal-associated membrane protein 
1; LAMP1) containing low-pH dependent hydrolases, forming autolysosomes. The 
pH of these vesicles lowers throughout this process, provoking the degradation of 
proteins within the autolysosome, including p62 and LC3. Autophagic flux, or the 
rate at which proteins are degraded by this pathway, can change in response to 
cellular stress and nutrient availability. Moreover, changes in autophagic flux can 
rapidly affect the localization and expression of proteins involved in this pathway 
(Loos et al., 2014). Accordingly, measurements of autophagy often require the use 
of inhibitors to capture proteins in transit within this pathway. Examples of well-
characterized autophagy inhibitors include leupeptin, a selective lysosomal 
protease inhibitor, ammonium chloride (NH4Cl), which raises vesicular pH, and 
bafilomycin A1 and chloroquine, which act by preventing the fusion of 
autophagosomes and lysosomes (Yang et al., 2013). 
Immunofluorescence protocol for in situ visualization of proteins within 
endomembrane vesicles 
 
Immunofluorescence is a common laboratory technique that involves the 
fixation, permeabilization, and antibody staining of cells to view proteins in situ 
using fluorescence microscopy. Traditional immunofluorescence protocols employ 
harsh detergents, like Triton-X 100, to permeabilize the cell membrane and allow 
for sufficient antibody intercalation to detect intracellular antigens. However, these 
detergents are known to destroy components of the endomembrane system, such 
as lysosomes, resulting in reduced visualization of antigens within vesicular 
lumens (Goldenthal et al., 1985). Accordingly, we developed an 
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immunofluorescence protocol specifically designed to avoid the destruction of 
membrane-bound organelles. This protocol was based on a previous technique 
designed to permeabilize fixed cells with digitonin, a selective detergent that 
punctures the plasma membrane while leaving endomembrane vesicles intact 
(Jaattela & Nylandsted, 2015). The protocol was as follows: 
Cells were washed with ice cold PBS supplemented with 40 mM NH4Cl to stop 
lysosomal protease activity and then fixed with PBS containing 3.4% 
paraformaldehyde and 0.1% glutaraldehyde for 5 minutes at room temperature. 
Cells were then permeabilized and blocked with 0.02% digitonin in LI-COR 
Odyssey Blocking Buffer containing 5% serum for 30 minutes at room temperature. 
The following steps were then performed in blocking buffer containing 0.02% 
digitonin and 5% serum: First, cells were incubated at room temperature for 1 hour 
in blocking buffer containing primary antibodies. Cells were then washed three 
times for five minutes with PBS and then incubated for 1 hour at room temperature 
in wash buffer containing secondary antibodies. Cells were then washed with PBS 
containing 1 µg/mL DAPI for five minutes at room temperature, followed by three 
washes with PBS before visualization. 
Autophagy stimulates p16 recruitment to lysosomes where it is degraded 
 
Autophagy stimulates the conversion of LC3-I to LC3-II, which is subsequently 
degraded within lysosomes. Accordingly, disrupting autophagy results in the 
accumulation of LC3-II within cells. Autophagy can be blocked by exposing cells 
to NH4Cl, which prevents the acidification of lysosomes, and leupeptin, a selective 
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lysosomal protease inhibitor (Yang et al., 2013). Protein analysis of RPE-1 cells 
via western blot demonstrated that 24-hour exposure to leupeptin combined with 
NH4Cl increased the ratio of LC3-II to LC3-I, confirming that lysosomal 
degradation was sufficiently blocked by this treatment (Figure 5A-B). 
To test if autophagy triggers p16 recruitment to lysosomes we performed 
immunofluorescence staining in RPE-1 cells and quantified the amount of p16 co-
co-localized with lysosomes. Using leupeptin+NH4Cl, we blocked lysosomal 
degradation while stimulating autophagy via serum starvation, hydrogen peroxide, 
or etoposide treatment. For all treatments, stimulation of autophagy in cells with 
active lysosomes produced few cytoplasmic p16 puncta (Figure 6A and 6C). 
However, blocking lysosomal degradation with leupeptin and NH4Cl for 24 hours 
resulted in the accumulation of cytoplasmic p16 puncta that co-localized with 
LAMP1, suggesting that a proportion of p16 was recruited to lysosomes (Figure 
6B and 6C). Stimulation of autophagy significantly increased the total number of 
p16 puncta per cell when lysosomal degradation was inhibited. Additionally, 
autophagy greatly increased the number of LAMP1 puncta per cell, suggesting an 
upregulation in lysosome production (Figure 6D). Although simultaneous 
autophagy activation and blocking increased the number of lysosomes per cell 
relative to blocking alone, the percentage of p16 puncta colocalized with 
lysosomes was not significantly changed, suggesting that most p16 aggregates 
that form were inside lysosomes (Figure 6E). 
Intriguingly, the number of p16-positive lysosomes in unstimulated cells was 
significantly increased by blocking autophagy, suggesting that p16 in RPE-1 cells 
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is always in autophagic flux. To test this, we performed protein analysis by western 
blot on cells treated with leupeptin and NH4Cl. Blocking lysosomal degradation for 
24 hours increased total p16 protein levels (Figure 6F and Figure 5C). 
Additionally, RT-qPCR performed 4 and 24 hours after treatment revealed that 
increased p16 protein in response to lysosome inhibition was not the result of de 
novo p16 transcription (Figure 6G). These results confirm that p16 can be 
degraded by lysosomes and is always in autophagic flux in RPE-1 cells.  
Together, these experiments demonstrate that stimulation of autophagy by 
serum starvation, hydrogen peroxide, or etoposide enhances p16 localization to 
lysosomes, and cells accumulate lysosomal p16 when autophagic degradation is 
disrupted. Furthermore, blocking lysosomal degradation increases total p16 
protein levels within cells without upregulating p16 transcription, demonstrating 
that p16 is degraded by autophagy. 
Disrupting autophagosome-lysosome fusion causes p16 aggregation 
within autophagosomes 
 
Autophagosomes are endomembrane vesicles that accumulate cargo 
destined for autophagy-mediated destruction. Lysosomes fuse to 
autophagosomes, forming autolysosomes, in which autophagosome-associated 
proteins and the content within them are degraded. Bafilomycin A1 and 
chloroquine are potent inhibitors of late stage autophagy that act by preventing 
fusion between autophagosomes and lysosomes (Yamamoto et al., 1998; X. D. 
Zhang, Qi, Wu, & Qin, 2013). Accordingly, autophagosome membrane marker LC3 
and other proteins destined for lysosomal degradation accumulate within stalled 
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autophagosomes (Bjorkoy et al., 2009). In Figure 6, we demonstrated that p16 
localizes to lysosomes when autophagy is stimulated by nutrient deprivation or 
cellular stress. We therefore asked if p16 is targeted to lysosomes by 
autophagosomes in response to autophagy.  
To test this, we first exposed RPE-1 cells to bafilomycin or chloroquine for 24 
hours to test if autophagy was blocked by these treatments. Protein analysis via 
western blot revealed a significant increase in LC3-II/LC3-I, which confirmed that 
autophagy was sufficiently blocked (Figure 5A-B). 
Next, we tested if stimulating autophagy while blocking autophagosome-
lysosome fusion via bafilomycin or chloroquine resulted in the accumulation of p16 
within autophagosomes. Immunofluorescence revealed that cytoplasmic p16 in 
control cells was diffuse, and autophagosome marker LC3 was either sparse or 
undetectable, a phenomenon known to be caused by rapid autophagic flux (Yoshii 
& Mizushima, 2017) (Figure 7A and 7C). However, disruption of autophagy via 
chloroquine or bafilomycin treatment caused aggregation of cytoplasmic p16 
puncta, which co-localized with LC3-positive puncta, indicating that p16 was 
accumulated within autophagosomes (Figure 7B-C and Figure 8). When 
autophagy was blocked, the number of LC3 puncta was significantly increased in 
cells exposed to serum starvation, hydrogen peroxide, or etoposide, suggesting 
that autophagosome production was amplified by autophagy stimulation (Figure 
7D). These treatments also significantly increased both the number of p16 puncta 
per cell and their colocalization with LC3 puncta, demonstrating that stimulation of 
autophagy drives p16 recruitment to autophagosomes (Figure 7E). To confirm that 
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these cytoplasmic puncta were p16, and to test if p16 itself affects autophagosome 
formation, we silenced p16 via siRNA and performed immunostaining to detect p16 
and LC3 accumulation in cells treated with chloroquine. Knockdown of p16 
eliminated p16 puncta without disrupting LC3 expression and formation in 
response to chloroquine, demonstrating that p16 is not required for 
autophagosome formation (Figure 9A-C). 
Finally, to test if p16 protein accumulates in cells with dysfunctional autophagy 
we treated RPE-1 cells with chloroquine or bafilomycin and performed protein 
analysis via western blot. Both chloroquine and bafilomycin were sufficient to 
increase total p16 protein levels after 24 hours (Figure 7F and Figure 5C). 
Additionally, RT-qPCR performed 4 and 24 hours after both treatments revealed 
that increased p16 protein in response to blocking autophagosome-lysosome 
fusion was not the result of de novo p16 transcription (Figure 7G).  
Together these results validate that p16 is shuttled through the autophagy 
pathway by autophagosomes, which implicates this pathway as a potential 
regulator of p16 and senescence. 
Autophagosome chaperone p62/SQSTM1 mediates p16 recruitment to 
lysosomes 
 
Autophagy can be selective for certain proteins and macromolecules targeted 
for degradation. For selective autophagy, ubiquitinated proteins or protein 
aggregates can be targeted to autophagosomes by ubiquitin-binding protein 
p62/SQSTM1. Although p16 does not contain a lysine residue, N-terminal 
ubiquitination of p16 has been reported (Ben-Saadon et al., 2004). Therefore, we 
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tested if p16 is selectively targeted to the autophagy pathway via p62 by studying 
p16 localization in response to the silencing of p62 by siRNA.  
First, we tested if p62 knockdown inhibited the autophagy pathway by silencing 
p62 and studying its effects on LC3 puncta formation. To do this, we co-treated 
RPE-1 cells with either siRNA targeting p62 or control scramble siRNA, as well as 
DMSO or the autophagy blocker chloroquine for 24 hours. Protein analysis via 
western blot confirmed robust knockdown of p62 24 hours after siRNA treatment 
(Figure 10A-B). Immunofluorescence revealed cytoplasmic LC3 and p62 puncta 
were present 24 hours after exposing cells to chloroquine and scramble siRNA, 
suggesting that these proteins accumulated within stalled autophagosomes 
(Figure 10C-D). Knockdown of p62 alone was not sufficient to induce LC3 puncta. 
Additionally, p62 knockdown ablated p62- but not LC3-puncta formation in 
response to chloroquine, suggesting that silencing p62 does not block LC3 
expression or autophagy. 
Next, we tested if p62 knockdown affects p16 recruitment to lysosomes. To do 
this, we repeated the experiment shown in Figure 3 by stimulating autophagy while 
inhibiting lysosomal degradation with leupeptin+NH4Cl in cells with silenced p62. 
Immunostaining for p16 and lysosome marker LAMP1 revealed that silencing of 
p62 resulted in the formation of fewer cytoplasmic p16 aggregates in response to 
autophagy stimulation and blocking lysosomal degradation compared to scramble-
treated control cells (Figure 11A-C). The number of LAMP1 puncta per cell was 
not significantly affected by p62 knockdown, suggesting that the loss of p16 
aggregates was not caused by disruption of lysosome formation (Figure 11D). Of 
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the fewer p16 puncta that did form, knockdown of p62 did not affect the percentage 
of those puncta localized to lysosomes, indicating that p16 was reaching 
lysosomes through additional pathways other than p62-mediated chaperoning 
(Figure 11E). Taken together, these results demonstrate that autophagy triggers 
recruitment of a proportion of p16 to lysosomes in a manner that is dependent on 




Figure 4. Autophagy pathway model depicting molecular markers and inhibitors. 
Autophagy chaperone protein p62 targets proteins destined for lysosome-mediated degradation to 
autophagosomes, which are identifiable by autophagosome membrane marker LC3. 
Autophagosomes fuse to lysosomes (identifiable by lysosome membrane marker LAMP1) 
containing low-pH dependent proteases, forming autolysosomes. The pH of these vesicles lowers 
throughout this process, provoking the degradation of proteins within the autolysosome, including 
p62 and LC3. Autophagy inhibitors bafilomycin A1 and chloroquine act by preventing the fusion of 
autophagosomes and lysosomes. Leupeptin inhibits proteases within lysosomes and 






Figure 5. Blocking autophagy using chemical inhibitors. 
RPE-1 cells were treated with etoposide (20 µM), H2O2 (200 µM), or serum starved for 24 hours. 
Additionally, each group was treated with DMSO or autophagy inhibitors bafilomycin (100 nM), 
chloroquine (40 µM), or leupeptin (100 µM) with NH4Cl (10 mM). Cells were then lysed for whole-
cell protein analysis via western blot. A) Representative western blot. B) Quantification of western 
blot showing quantified LC3-II/LC3-I. Statistical significance determined using three-way ANOVA 
(n = 3). * = p<0.05 relative to respective DMSO. All error bars = standard deviation. C) 
Representative western blot for p16 protein after autophagy inhibition. Cells were treated with 
DMSO, bafilomycin (100 nM), chloroquine (40 µM), or leupeptin (100 µM) with NH4Cl (10 mM) for 




Figure 6. Autophagy recruits p16 to lysosomes. 
RPE-1 cells were treated with etoposide (20 μM), H2O2 (200 μM), or serum starved for 24 hours. 
Additionally, each group was treated with DMSO or leupeptin (100 μM) and NH4Cl (10 mM). Cells were 
fixed and permeabilized with digitonin for immunofluorescence staining. A) Cells treated with DMSO, in 
addition to the treatments previously described. DAPI in blue; p16 in red; LAMP1 in green. Scale bars = 
10 μm. B) Cells treated with leupeptin+NH4Cl, in addition to the treatments previously described. C) 
Quantification of p16 puncta per cell. D) Quantification of LAMP1 puncta per cell. E) Quantification of % 
colocalization for LEU+NH4Cl treatment groups, calculated as the percent of total p16 puncta per cell 
co-localized with LAMP1 puncta. For C-E, results are the mean of sample means obtained from 9 images 
per group with at least 100 cells per image. Significance determined by two-way ANOVA and Bonferonni 
post-hoc (n = 9). ns = p>0.01 and * = p<0.01. F) Quantification of western blots for cells treated with 
leupeptin (100 μM) and NH4Cl (10 mM) for 24 hours. Proteins normalized to actin. Significance 
determined by one-way ANOVA (n = 3). * = p<0.05. G) qPCR for cells treated with leupeptin (100 μM) 
and NH4Cl (10 mM) for 4 or 24 hours. Transcripts normalized to actin. Significance determined by two-




Figure 7. Blocking autophagy results in p16 accumulation within autophagosomes. 
RPE-1 cells were treated with etoposide (20 µM), H2O2 (200 µM), or serum starved for 24 hours. 
Additionally, each group was treated with DMSO, bafilomycin (100 nM), or chloroquine (40 µM). Cells 
were then fixed and permeabilized with digitonin for immunofluorescence staining. A) Cells treated with 
DMSO, in addition to the treatments previously described. DAPI shown in blue; p16 shown in red; LC3 
shown in green. Scale bars = 10 μm. B) Cells treated with chloroquine, in addition to the treatments 
previously described. C) Quantification of p16 puncta per cell. D) Quantification of LC3 puncta per cell. 
E) Quantification of % colocalization, calculated as the percent of total p16 puncta per cell co-localized 
with LC3 puncta. For C-E, results are the mean of sample means obtained from 10 images per group 
with at least 100 cells per image. Statistical significance determined by two-way ANOVA and Bonferonni 
correction (n = 10). ns = p>0.01 and * = p<0.01 relative to respective DMSO. F) Quantification of western 
blots for cells treated with bafilomycin (100 nM) or chloroquine (40 µM) for 24 hours. Proteins normalized 
to actin. Statistical significance determined by one-way ANOVA (n = 3). * = p<0.05. G) RT-qPCR for 
cells treated with bafilomycin (100 nM) or chloroquine (40 µM) for 4 or 24 hours. Transcripts normalized 
to actin. Statistical significance determined by two-way ANOVA (n = 3). ns = p>0.05 relative to respective 





Figure 8. Representative immunofluorescence images for Figure 7C-E for cells treated with 
bafilomycin. 
RPE-1 cells were treated with etoposide (20 µM), H2O2 (200 µM), or serum starved. Additionally, 
each group was treated with bafilomycin (100 nM). After 24 hours, cells were then fixed and 
permeabilized with digitonin for immunofluorescence staining. DAPI shown in blue; p16 shown in 






Figure 9. siRNA knockdown of p16 does not disrupt autophagasome formation. 
A) RPE-1 cells were treated with 40 µM chloroquine to block autophagy and transfected with 
siRNA-p16 (si-p16) or siRNA-scramble control (Sc) for 24 hours. Cells were then fixed, 
permeabilized with digitonin, and stained for DAPI (blue), p16 (red) and LC3 (green). Scale bars = 
10 μm.  B) Quantification of puncta segmented per cell for p16 knockdown experiment. C) Western 






Figure 10. siRNA knockdown of p62 does not induce or disrupt autophagasome formation. 
RPE-1 cells were treated 40 µM chloroquine to block autophagy and transfected with siRNA-p62 
or siRNA-scramble control for 24 hours. Whole cell lysates were then obtained and used for protein 
analysis via western blot. A) Representative western blot for p62 knockdown via siRNA. B) 
Quantification of p62 knockdown western blot. Statistical significance performed using two-tailed 
student’s t-test. n = 3. C) RPE-1 cells were treated with DMSO or 40 µM chloroquine to block 
autophagy and transfected with siRNA-p62 (si-p62) or siRNA-scramble control (Sc) for 24 hours. 
Cells were then fixed, permeabilized with digitonin, and stained for DAPI (blue), LC3 (green), and 
p62 (magenta). Scale bars = 10 μm. D) Quantification of puncta per cell from immunofluorescence 





Figure 11. p16-lysosome recruitment is mediated by p62. 
RPE-1 cells transfected with siRNA-p62 or scramble control (Sc) were treated with etoposide (20 μM), 
H2O2 (200 μM), or serum starved for 24 hours. Additionally, each group was treated with leupeptin (100 
μM) and NH4Cl (10 mM). Cells were then fixed and permeabilized with digitonin for immunofluorescence 
staining. A) Cells treated with leupeptin+NH4Cl and scramble control, in addition to the treatments 
previously described. DAPI shown in blue; p16 shown in red; LAMP1 shown in green. Scale bars = 10 
μm. B) Cells treated with leupeptin+NH4Cl and siRNA targeting p62, in addition to the treatments 
previously described. C) Quantification of p16 puncta per cell. D) Quantification of LAMP1 puncta per 
cell. E) Quantification of % colocalization, calculated as the percent of total p16 puncta per cell co-
localized with LAMP1 puncta. For C-E, results are the mean of sample means obtained from 9 images 
per group with at least 100 cells per image. Statistical significance determined by two-way ANOVA and 






CHAPTER 4: HIGH-CONTENT EPIGENETIC DRUG SCREEN FOR 




Modifications in the epigenetic profile of p16 have been linked to both 
repression and expression of p16. For example, two well-known modulators of p16 
are CpG island methylation and histone methylation via Polycomb repression 
complexes.  Both of these epigenetic modifiers play a role in p16 repression, which 
in turn prevents cellular senescence and contributes to tumor metastasis. 
CpG island methylation 
CpG islands are regions of DNA where cytosine and guanine occur in a 
linear sequence. The cytosine in CpG sites can be methylated by 
methyltransferases to form 5-methylcytosine (5mC), which is a classic epigenetic 
mark for gene silencing. Repression of p16 via hypermethylation of CpG sites has 
been found in cancer cell lines that do not contain homozygous deletions or 
mutations at the p16/CDKN2A locus (Gonzalez-Zulueta et al., 1995). Furthermore, 
a meta-analysis of studies assessing the impact of p16 expression on cancer 
survival found that p16 hypermethylation was significantly associated with poor 




Polycomb repression complexes 
Polycomb-group proteins form complexes that are linked to the epigenetic 
silencing of genes via histone methylation (Lund & van Lohuizen, 2004). Bmi-1 is 
transcription factor and member of the Polycomb repressor complex 1 (PRC1) that 
silences gene expression by inducing H3K27 methylation (Abdouh, Hanna, El 
Hajjar, Flamier, & Bernier, 2016). Bmi-1 was found to represses p16 directly by 
binding to a Bmi1-responding element (BRE) within the p16 promoter (Kotake et 
al., 2007). Knockout of Bmi-1 resulted in upregulation of p16 and decreased 
proliferation. Furthermore, silencing of EZH2, a catalytic subunit of Polycomb 
repressor complex 2 (PRC2) also significantly upregulated p16 transcription 
(Kotake et al., 2007). 
Epigenetic drug screens can find novel targets for disease therapies 
 
The role of epigenetics in disease etiology and pathology is well known 
(Moosavi & Motevalizadeh Ardekani, 2016; Ptak & Petronis, 2008). Accordingly, 
the use of small molecules targeting epigenetic factors has become a popular 
technique for disease treatment (Popovic & Licht, 2012; Ptak & Petronis, 2008). 
While the use of epigenetic-therapy has gained wide-spread use, high-throughput 
platforms for discovering new epigenetic-targeting drugs must be developed to 
ensure that physicians have access to a robust library of compounds for treating a 
variety of disease types. As such, epigenetic drug screens have been employed 
to identify potential targets for therapeutic intervention (Wiggers et al., 2019; Wu 
et al., 2019).  
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Unlike gene-therapies, in which diseases are treated by targeting mutations 
within a static DNA sequence, epigenetic-therapies require targeting a dynamic 
and complex system of interacting proteins and genes in order to obtain a specific 
chromatin state. Consequently, the ability to perform high-content screens for 
epigenetic regulators of a protein of interest is limited by the ability to identify 
changes in protein expression with temporal resolution. In response to the need 
for a dynamic readout of expression, researchers have begun to employ live-cell 
fluorescent protein reporter cell lines to perform high-content screens for 
epigenetic regulators (Headley et al., 2019). The development of an endogenous 
p16 fluorescent reporter cell line provides researchers with a useful tool to perform 
high-content drug screens for modulators of p16 expression and discover potential 
therapeutic targets for senescence, cancer, and aging-associated diseases. 
Epigenetic drug screening using RPE p16-mCherry cells 
 
To discover the epigenetic factors that control p16 expression, a high-
content drug screen was performed on a p16-mCherry reporter cell line. To test 
the robustness of the screening platform and establish control treatments, RPE-1 
cells containing an endogenous p16-mCherry fusion protein (RPE p16-mCherry) 
were first treated with DMSO, siRNA targeting p16, and etoposide, a known p16 
activator. Treatments were dispensed into a 384-well plate with etoposide 
concentrations ranging from 2.5-20 μM. After 48 hours, cells were imaged and 
changes in p16 protein expression between treatments were plotted via heat map 
by quantifying the overall mean per well of mean p16-mCherry fluorescence signal 
per cell (Figure 12A). Each treatment was tested for its effects on p16-mCherry 
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expression by Z-factor testing for statistical significance relative to DMSO (Figure 
12B). siRNA-p16 and 10 μM etoposide for 48 hours were determined to be 
adequate negative and positive controls for p16-mCherry expression, respectively 
(Z-factor > 0). 
Next, RPE p16-mCherry cells were treated for 48 hours with 64 drugs that 
inhibit various epigenetic modifiers, including histone deacetylases (HDACs), 
methyltransferases (HMTs), and acetyltransferases (HATs), as well as specific 
inhibitors of polycomb repressor family proteins, including Bmi-1 and EZH2 (Table 
1). These drugs were dispensed into a 384-well plate with concentrations ranging 
from 0.08-50 μM. Etoposide and siRNA knockdown of p16 were used as activator 
and repressor controls, respectively. Changes in p16 expression between 
treatments were detected by quantifying the overall mean per well of mean p16-
mCherry fluorescence per cell using image analysis software. Potency as an 
epigenetic modulator of p16 was determined by Z-factor testing for statistical 
significance. 
The screen revealed several epigenetic-targeting drugs to be repressors or 
activators of p16 (Figure 13A-B and Table 2). Potent downregulation of p16 
occurred in response to HDAC inhibitors Panobinostat, Romidepsin, CAY10603, 
Chidamide, Entinostat, TSA, LAQ824 (Dacinostat), and SAHA (Vorinostat). 
Targeting members of the polycomb repressor complex resulted in upregulation of 
p16. For example, p16 increased in response to BMI-1 inhibitor GSK126, and 
EZH2 inhibitors PTC-209 and UNC1999. Upregulation of p16 also occurred in 
response to Menin-MLL inhibitor, MI-503, and Brpf1 inhibitor, OF-1. Inhibiting 
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various members of the BET (Bromodomain and extraterminal domain) family 
resulted in both up- and downregulation of p16: OTX015 and I-BET151 caused a 
decrease in p16, whereas inhibiting Bromosporine and JQ1 induced p16 
expression. Lastly, p16 expression increased in response to HCl-2509 (SP2509), 
an inhibitor of Lysine-specific demethylase 1 (LSD1). 
To confirm the validity of the screen results, selected epigenetic drugs that 
had a Z-score > 0 relative to DMSO were verified in a non-reporter cell line (RPE-




Figure 12. Preliminary test for establishing controls for epigenetic drug screen 
A) Quantified fluorescence readout from a 384-well plate containing RPE p16-mCherry cells treated 
for 48 hours with DMSO, siRNA-p16, or etoposide (Etop). Heat map represents total mean per well 
of mean p16-mCherry fluorescence per cell relative to DMSO control group (green = no change, 
yellow = higher fluorescence, blue = lower fluorescence). Units in relative fluorescence units. Mean 
fluorescence = integrated pixel intensity/total pixels per cell. B) Bar graph showing quantified mean 
p16-mCherry fluorescence per treatment group. Error bars = standard error of the mean (n=64).  
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TABLE 1: Epigenetic compound reference 
WELL COMMON NAME TARGET CLASS 
A:3 Panobinostat HDACs HDAC 
A:4 BAY-598 SMYD2 HMT 
A:5 LLY-507 SMYD2 HMT 
A:6 EPZ011989 EZH2 HMT 
B:3 Cl-994 (Tacedinaline) HDAC1,2,3 HDAC 
B:4 Romidepsin HDACs HDAC 
B:5 OICR9429 WDR5 Kme Reader 
B:6 SGC0946 DOT1L HMT 
C:3 UNC0642 G9a/GLP HMT 
C:4 UNC0638 G9a/GLP HMT 
C:5 C646 p300 (HAT) Other 
C:6 A-366 G9a/GLP HMT 
D:3 I-CBP112 CREBBP/EP300 bromodomain 
D:4 CAY10603 HDAC6 HDAC 
D:5 Olaparib PARP (poly ADP ribose polymerase) Other 
D:6 EPZ-6438 EZH2 HMT 
E:3 LP99 BRD9/7 bromodomain 
E:4 GSK591 PRMT5 HMT 
E:5 Chidamide HDACs HDAC 
E:6 OTX015 BET family bromodomain 
F:3 I-BRD9 BRD9 bromodomain 
F:4 GSK-LSD1 LSD1 Demethylase 
F:5 Entinostat HDAC1,3 HDAC 
F:6 MI-503 Menin-MLL Other 
G:3 MS023 Type I PRMT HMT 
G:4 GSK126 EZH2 HMT 
G:5 IOX2 PHD (Prolyl hydroxylase) Other 
G:6 EI1 EZH2 HMT 
H:3 UNC3866 CBX4/7 (CBXs) Kme Reader 
H:4 GSK484 PAD-4 (Protein Arg deiminase 4) Other 
H:5 PFI-1 BET family bromodomain 
H:6 BAZ2-ICR BAZ2A/B bromodomain 
I:3 GSK2801 BAZ2A/B bromodomain 
I:4 GSK-J4 (J1) JMJD3/UTX Demethylase 
I:5 I-BET151 BET family bromodomain 
I:6 KDOAM25 JARID1/KDM5 Demethylase 
J:3 Bromosporine bromodomains bromodomain 
J:4 Decitabine DNMTs Other 
J:5 SGC-CBP30 CREBBP/EP300 bromodomain 
J:6 UNC1215 L3MBTL3 Kme Reader 
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TABLE 1: Epigenetic compound reference (continued) 
WELL COMMON NAME TARGET CLASS 
K:3 TSA HDACs (except 8) HDAC 
K:4 I-BET762 (GSK525762A) BET family bromodomain 
K:5 PFI-4 BRPF1 bromodomain 
K:6 BI-9564 BRD9/7 bromodomain 
L:3 A-196 SUV420H1/H2 HMT 
L:4 IOX1 2-OG (OxoGlutarate oxygenases) Other 
L:5 PFI-3 SMARCA2/4, PBI(5) bromodomain 
L:6 SGC707 PRMT3 HMT 
M:3 GSK343 EZH2 HMT 
M:4 MS049 PRMT 4&6 HMT 
M:5 (R)-PFI-2 SETD7 HMT 
M:6 UNC1999 EZH2/EZH1 HMT 
N:3 EPZ-5676 DOT1L HMT 
N:4 LAQ824 (Dacinostat) HDACs HDAC 
N:5 EPZ015666 PRMT5 HMT 
N:6 (+)-JQ1 BET family bromodomain 
O:3 OF-1 BRPF family bromodomain 
O:4 SAHA (Vorinostat) HDAC1,2,3,6 HDAC 
O:5 PTC-209 BMI-1 Other 
O:6 BAY299 BRD1/TAF1 bromodomain 
P:3 PCI-34051 HDAC8 HDAC 
P:4 NI-57 BRPF family bromodomain 
P:5 HCl-2509 (SP2509) LSD1 Demethylase 






Figure 13. Epigenetic drug screen for modulators of p16 expression. 
RPE p16-mCherry cells were treated with epigenetic targeting drugs, DMSO, siRNA-p16, or 
etoposide for 48 hours. A) Heat map represents total mean per well of mean p16-mCherry 
fluorescence per cell relative to DMSO control group (green = no change, yellow = higher 
fluorescence, blue = lower fluorescence). White wells = >50% cell death. Mean fluorescence = 
integrated pixel intensity/total pixels per cell. Units in relative fluorescence units. B) Bar graph 
showing quantified mean p16-mCherry fluorescence for selected treatment groups where Z-factor 
> 0 relative to DMSO control.  
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TABLE 2: Modulators of p16 from epigenetic drug screen 
WELL COMMON NAME TARGET CLASS EFFECT ON P16 
A:3 Panobinostat HDACs HDAC INHIBITOR 
B:4 Romidepsin HDACs HDAC INHIBITOR 
D:4 CAY10603 HDAC6 HDAC INHIBITOR 
E:5 Chidamide HDACs HDAC INHIBITOR 
E:6 OTX015 BET family bromodomain INHIBITOR 
I:5 I-BET151 BET family bromodomain INHIBITOR 
F:5 Entinostat HDAC1,3 HDAC INHIBITOR 
K:3 TSA HDACs (except 8) HDAC INHIBITOR 
N:4 LAQ824 (Dacinostat) HDACs HDAC INHIBITOR 
O:4 SAHA (Vorinostat) HDAC1,2,3,6 HDAC INHIBITOR 
F:6 MI-503 Menin-MLL Other ACTIVATOR 
G:4 GSK126 EZH2 HMT ACTIVATOR 
J:3 Bromosporine bromodomains bromodomain ACTIVATOR 
M:6 UNC1999 EZH2/EZH1 HMT ACTIVATOR 
N:6 (+)-JQ1 BET family bromodomain ACTIVATOR 
O:3 OF-1 BRPF family bromodomain ACTIVATOR 
O:5 PTC-209 BMI-1 Other ACTIVATOR 






Figure 14. Validation of epigenetic drug screen. 
RPE-1 cells were treated with epigenetic targeting drugs, DMSO, siRNA-p16, or etoposide. RNA 
lysates were collected after 48 hours. Converted cDNA was then used for RT-qPCR. Results show 
quantified p16 transcript fold-change relative to DMSO control. Error bars = standard deviation from 













































CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions and future directions for studying the effects of autophagy on 
p16 expression and localization 
 
The experiments presented in this dissertation demonstrate that the 
localization and degradation of the p16 protein is regulated in part by the 
autophagy-lysosomal pathway in human RPE-1 cells. Live-cell experiments using 
a p16-mCherry fluorescent reporter revealed that autophagy stimulation induces 
lysosomal p16 enrichment within 4 hours and can be triggered by serum starvation, 
oxidative stress by hydrogen peroxide, and genotoxic stress by the 
chemotherapeutic agent etoposide. Blocking autophagy using leupeptin, 
chloroquine, or bafilomycin greatly increases the amount of p16 inside lysosomes, 
demonstrating that p16 can be degraded by this pathway. Additionally, we found 
that p16 is recruited to lysosomes by the chaperone protein p62. Together, these 
results reveal an unappreciated mode of regulation of the p16 protein in human 
cells. 
Traditionally, protein localization has been studied with immunohistological 
experiments using antibodies targeting the protein of interest.  However, these 
methods require the fixation of cells, which prevents temporal analysis of protein 
expression and localization. The autophagy pathway and endomembrane system 
is dynamic, mobile, and known to induce drastic changes in protein localization in 
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a relatively short time-frame. By creating an endogenous p16-mCherry reporter in 
human cells, we have contributed a novel tool for examining p16 expression and 
localization over time. Use of this reporter in future experiments will help to further 
our understanding of p16 dynamics in response to a multitude of chemotherapeutic 
agents, cellular stresses, and inducers of autophagy dysfunction. 
Further study is required to identify the precise mechanisms that control p16 
localization. For example, it is not known which domains on the p16 protein are 
responsible for autophagosomal and lysosomal recruitment. While we have found 
that p62 promotes p16 recruitment to lysosomes, the endomembrane-transport 
system is complex, with many additional chaperone proteins and post-translational 
modifiers involved in recruiting, sorting, and shuttling cargo between different 
compartments of the cell. Determining the specific factors that control p16 
transport could reveal potential drug targets for disease and anti-aging therapies. 
We found that stimulating autophagy in RPE-1 cells while blocking 
lysosomal degradation led to a significant increase in lysosomal p16 aggregates. 
Interestingly, blocking autophagy also induced the formation of lysosomal p16 
aggregates to some extent even when autophagy was not stimulated. This 
suggests that p16 is continually in autophagic flux in these cells, which may explain 
how proliferating cells can sustain basal levels of p16 expression without inducing 
cell-cycle arrest. Additionally, we have demonstrated that activation of autophagy 
recruits p16 to lysosomes for degradation, which may prevent p16-induced 
senescence despite increases in p16 expression stimulated by cellular stress. Our 
study expands this relationship to the tumor suppressor p16, and links p16 
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localization to lysosomal function, which both serve as key regulators of 
senescence, disease, and aging.  
Since the p16 protein has long been known to promote cell cycle arrest 
through inhibition of CDK4/6 in the nucleus, these results suggest a potential 
competition between the autophagy and senescence pathways through the 
sequestration of p16. Under this hypothetical model, stress induces the production 
of p16, which is quickly recruited to autophagosomes and degraded by lysosomes 
via the autophagy pathway. Over time, either through enhanced transcriptional 
activity or through p16 protein localization outside of lysosomes, p16 is able to 
enter the nucleus to bind to CDK4/6 and arrest the cell cycle. However, if the 
autophagy pathway is inhibited, p16 degradation is perturbed, which could lead to 
premature senescence. From this model, we posit that autophagy “buys time” for 
cells undergoing stress to determine whether the damage is manageable and cells 
are able to resume proliferation once the stress conditions are eliminated. 
Alternatively, if stress conditions persist, or if autophagy is dysregulated, the cell 
enters senescence. Future studies will be necessary to determine whether 
sequestration of p16 through the autophagy-lysosomal pathways reduces a cell’s 
tendency to undergo senescence. 
Finally, the observation that p16 localizes to and is degraded by lysosomes 
represents a potentially novel thread of research for cancer cell biology. Commonly 
used chemotherapeutic drugs can induce increases in p16 expression in patients, 
but the effect of these agents on p16 localization in single cells has not been fully 
explored. Understanding how these therapies affect p16 localization could 
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illuminate how these treatments work at a mechanistic level. The ability to control 
senescence and attenuate cell growth via combined treatment with 
chemotherapeutics and well-established autophagy inhibitors could have major 
implications for cancer treatment. Beyond this application, the ability to slow or 
prevent senescence in healthy proliferating cells, such as stem cells, could lead to 
potential new therapies for other age-related diseases. In addition, we believe it is 
worth exploring the role of p16 in lysosomal storage diseases, which account for 
dozens of disorders associated with the brain, skin, heart, and central nervous 
system. 
Conclusions and future directions for epigenetic screening for regulators 
of p16 
 
Our high-content screen for epigenetic regulators of p16 revealed several 
epi-targeting drugs that repressed or activated p16. Furthermore, the development 
of a live fluorescent p16 reporter cell line provided a novel screening tool that could 
be utilized for future drug discovery projects that target regulators of p16 
expression.  
The screen included several drug targets that are known to regulate p16 
expression. As stated in Chapter 4, histone methylation by polycomb repressor 
complex binding is a known method of epigenetic regulation of the p16 locus. As 
expected, p16 expression was upregulated when polycomb-group proteins BMI-1 
and EZH2 were inhibited. Similarly, Menin-MLL inhibition by MI-503 also led to the 
upregulation of p16. Menin-MLL is a histone methyltransferase complex that is 
specific for histone H3K4 and is implicated in regulating cell proliferation and 
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cancer (Dimartino & Cleary, 1999; Yokoyama et al., 2004). Menin-MLL has been 
reporter to regulate the expression of a variety of cyclin-dependent kinase 
inhibitors, including p16INK4A, p27Kip1 and p18Ink4c (Kotake, Zeng, & Xiong, 2009; 
Milne et al., 2005). Lastly, JQ-1, a potent BET inhibitor, induced p16 expression. 
JQ-1 has been reported to inhibit H3K27me3 activity at the p16 promoter, which 
upregulates p16 expression (Y. Zhang et al., 2018). Although the targets of these 
small molecules have previously been reported to affect p16 expression, these 
results confirm the accuracy and robustness of our screening platform, and identify 
specific compounds that could potentially serve as therapeutics for p16-associated 
diseases. 
The most intriguing result from our screen was the inhibition of p16 
expression in response to HDAC inhibitors. HDAC inhibitors increase acetylation 
of lysine residues on histone proteins and have been used in anti-cancer therapies 
(Kim & Bae, 2011). Deacetylation of histones results in the tightening of chromatin 
(Grunstein, 1997). Consequently, HDAC inhibitors are classified as compounds 
that inhibit the deacetylation of histones, and are thus implicated in the activation 
of gene transcription. Therefore, it is intriguing that our screen revealed a wide 
array of HDAC inhibitors that led to the potent repression of p16 expression. One 
possible explanation for this occurrence is that these compounds upregulated the 
expression of cis-regulatory elements that repress p16. For example, ANRIL 
(antisense non-coding RNA in the INK4 locus) is a long non-coding RNA that is 
linked to repression of the INK4/ARF locus (Yap et al., 2010). ANRIL consists of 
19 exons spanning 126 kb near INK4/ARF and has been reported to recruit 
48 
 
polycomb repressor complexes 1 and 2, which are known to silence p16 
transcription. Future studies should focus on determining if the HDAC inhibitors 
used in this screen upregulate repressors of p16, such as ANRIL. 
The identification of these epigenetic modifiers, which strongly control p16 
expression, could lead to the development of therapeutic drugs that control cellular 
senescence. The ability to prevent healthy cells from senescing, while inducing 
cell-cycle arrest in transformed cells, is a major goal for both the aging and cancer 
fields. As such, this project provides a strong foundation for future research aimed 
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